This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Phase III study of docetaxel and atrasentan versus docetaxel and placebo for patients with advanced hormone refractory prostate cancer

http://hawaii.eagle-i.net/i/00000130-dddf-9670-9953-50a980000000

ClinicalTrials.gov url

http://www.clinicaltrials.gov/ct2/show/NCT00134056?term=S0421&rank=1
Intervention

Atrasentan hydrochloride
Intervention

Prednisone
Intervention

Docetaxel
Intervention

Placebo
Additional Topic(s)

Bone metastases
Resource Description

This randomized phase III trial is studying docetaxel, prednisone, and atrasentan to see how well they work compared to docetaxel and prednisone in treating patients with stage IV prostate cancer and bone metastases that did not respond to previous hormone therapy.
Contact

Berenberg, Jeffrey
PI

Berenberg, Jeffrey
Topic

prostate cancer
Funded by

SWOG
Phase

Phase 3 clinical trial
Performed by

Clinical Protocol & Data Management Shared Resource

Inferred Types from the eagle-i Ontology (What is an ontology?)

Provenance Metadata About This Resource Record